Scarica l'app Stockscreener
2.15
7.33%
-0.17
Dopo l'orario di chiusura:
2.15
Kyverna Therapeutics Inc Borsa (KYTX) Ultime notizie
Integral Health Asset Management LLC Acquires 150,000 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases - Seeking Alpha
Kyverna Therapeutics Provides Business Update And Reports First Quarter 2025 Financial Results - marketscreener.com
Kyverna's Autoimmune Pipeline Hits Major Milestones: SPS Trial Full, MG Phase 3 Gets FDA Green Light - Stock Titan
KYTX Stockholders Have Opportunity to Lead Kyverna Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Kyverna Therapeutics (KYTX) to Release Quarterly Earnings on Tuesday - MarketBeat
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics - ACCESS Newswire
Kyverna Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights – KYTX - ACCESS Newswire
Kyverna Therapeutics Inc expected to post a loss of $1.11 a shareEarnings Preview - TradingView
Class Action Filed Against Kyverna Therapeutics, Inc. (KYTX)February 7, 2025 Deadline to Join – Contact Levi & Korsinsky - ACCESS Newswire
KYVERNA THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Ky - ACCESS Newswire
Shareholders that lost money on Kyverna Therapeutics, Inc.(KYTX) should contact Levi & Korsinsky about pending Class ActionKYTX - ACCESS Newswire
Shareholders that lost money on Kyverna Therapeutics, Inc.(KYTX) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More - ACCESS Newswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Kyverna Therapeutics, Inc. (KYTX) Shareholders - ACCESS Newswire
Shareholders of Kyverna Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your RightsKYTX - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Brokerages Set Kyverna Therapeutics, Inc. (NASDAQ:KYTX) PT at $18.33 - MarketBeat
Kyverna Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your RightsKYTX - ACCESS Newswire
KYTX Stock Price and Chart — NASDAQ:KYTX - TradingView
Gilead Sciences Inc. Purchases New Position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
JPMorgan Chase & Co. Sells 220,915 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Sold by Franklin Resources Inc. - MarketBeat
Notice to Long-Term Shareholders of Kyverna Therapeutics, - GlobeNewswire
Notice to Long-Term Shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Methode - Bluefield Daily Telegraph
Notice to Long-Term Shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Methode Electronics, Inc. (NYSE: MEI); ModivCare, Inc. (NASDAQ: MODV); and Monolithic Power Systems, Inc. (NASDAQ: MPWR)Grabar Law Office Is Investigating Claims - TradingView
Investigation announced for Long-Term Investors in shares of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) - openPR.com
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):